JP2007524708A - 血管新生を阻害するラクトアルブミン - Google Patents

血管新生を阻害するラクトアルブミン Download PDF

Info

Publication number
JP2007524708A
JP2007524708A JP2007500287A JP2007500287A JP2007524708A JP 2007524708 A JP2007524708 A JP 2007524708A JP 2007500287 A JP2007500287 A JP 2007500287A JP 2007500287 A JP2007500287 A JP 2007500287A JP 2007524708 A JP2007524708 A JP 2007524708A
Authority
JP
Japan
Prior art keywords
lactalbumin
biologically active
hamlet
tumor
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007500287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524708A5 (cg-RX-API-DMAC10.html
Inventor
カタリーナ・スヴァンボルイ
Original Assignee
ハムレット・ファルマ・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0404369A external-priority patent/GB0404369D0/en
Priority claimed from GB0404339A external-priority patent/GB0404339D0/en
Priority claimed from GB0404358A external-priority patent/GB0404358D0/en
Application filed by ハムレット・ファルマ・アーベー filed Critical ハムレット・ファルマ・アーベー
Publication of JP2007524708A publication Critical patent/JP2007524708A/ja
Publication of JP2007524708A5 publication Critical patent/JP2007524708A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007500287A 2004-02-26 2005-02-24 血管新生を阻害するラクトアルブミン Pending JP2007524708A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0404369A GB0404369D0 (en) 2004-02-26 2004-02-26 Novel therapies
GB0404339A GB0404339D0 (en) 2004-02-26 2004-02-26 Therapeutic treatment
GB0404358A GB0404358D0 (en) 2004-02-26 2004-02-26 Therapeutic treatment
PCT/GB2005/000685 WO2005082406A1 (en) 2004-02-26 2005-02-24 Lactalbumin for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
JP2007524708A true JP2007524708A (ja) 2007-08-30
JP2007524708A5 JP2007524708A5 (cg-RX-API-DMAC10.html) 2008-03-21

Family

ID=34915949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500287A Pending JP2007524708A (ja) 2004-02-26 2005-02-24 血管新生を阻害するラクトアルブミン

Country Status (4)

Country Link
US (1) US20080039381A1 (cg-RX-API-DMAC10.html)
EP (1) EP1727561A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007524708A (cg-RX-API-DMAC10.html)
WO (1) WO2005082406A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
WO2008138348A1 (en) * 2007-05-09 2008-11-20 Nya Hamlet Pharma Ab Preparation of complexed lactalbumin
US20100112702A1 (en) * 2008-02-25 2010-05-06 Klein Benjamin Y Method designed to divert glucose away from the glycolytic pathway
WO2009135494A2 (en) * 2008-05-09 2009-11-12 Nya Hamlet Pharma Ab Alpha-lactalbumin composition for the treatment of actinic keratosis
WO2010131237A1 (en) * 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
WO2014023976A1 (en) * 2012-08-09 2014-02-13 Hamlet Pharma Ab Prophylactic and nutraceutical therapy
WO2024075003A1 (en) 2022-10-03 2024-04-11 Linnane Pharma Ab A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524535A (ja) * 1997-11-27 2001-12-04 カタリーナ・スヴァンボルイ 治療剤
WO2003074547A2 (en) * 2002-03-07 2003-09-12 Catharina Svanborg Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2188903A (en) * 1938-12-03 1940-02-06 Dow Chemical Co Polystyrene compositions
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
GB0211658D0 (en) * 2002-05-22 2002-07-03 Svanborg Catharina Novel therapies and methods of screening for therapeutic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524535A (ja) * 1997-11-27 2001-12-04 カタリーナ・スヴァンボルイ 治療剤
WO2003074547A2 (en) * 2002-03-07 2003-09-12 Catharina Svanborg Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor

Also Published As

Publication number Publication date
US20080039381A1 (en) 2008-02-14
EP1727561A1 (en) 2006-12-06
WO2005082406A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
Zhou et al. Injectable extracellular vesicle-released self-assembling peptide nanofiber hydrogel as an enhanced cell-free therapy for tissue regeneration
CN107921062B (zh) 组织修复和再生方法
ES2677005T3 (es) Composición parenteral que comprende microesferas con un diámetro entre 10 y 20 micras
JP2021520373A (ja) Cgrpを阻害する際に使用するための神経毒素
Xu et al. Skin-permeable liposome improved stability and permeability of bFGF against skin of mice with deep second degree scald to promote hair follicle neogenesis through inhibition of scar formation
PT1526867E (pt) Eritropoietina em doses sub-policitémicas
CZ20023913A3 (cs) Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
CN113116928B (zh) 预防或治疗眼疾的组合物及方法
JP7509865B2 (ja) アネキシンa5の用途
KR20200140277A (ko) 허혈 재관류 손상 예방 및/또는 치료용 한약 조성물
CA2951686C (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject
Li et al. MG53/GMs/HA-Dex neural scaffold promotes the functional recovery of spinal cord injury by alleviating neuroinflammation
TW201121992A (en) Suppression of cancer metastasis
WO2024193322A1 (zh) 利培酮在治疗器官纤维化中的应用
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
You et al. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis
US20080039381A1 (en) Lactalbumin for Inhibiting Angiogenesis
CN116004527B (zh) 一种间充质干细胞凋亡小泡递释系统及其构建方法和应用
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN1960747A (zh) 用于抑制血管生成的乳清蛋白
ES2405333T3 (es) Agente terapéutico para la regeneración del complejo dentina-pulpa dental
JP2005104910A (ja) 血管新生剤
CN116036306B (zh) 一种基于全过程调节的共递送脂质体及其制备方法和应用
CN118873629B (zh) 醋酸拉唑肽在制备促进成骨药物中的用途
WO2007122280A1 (es) Uso del factor de crecimiento de hígado (lgf) como regenerador tisular pleiotrópico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110712